HOME >> BIOLOGY >> NEWS
Physics tip sheet #13 May 15, 2002

ion of neutron stars from collapsing supernovae are some of the most dramatic processes in stellar evolution. In a neutron star, high densities cause matter to form a uniform liquid but just before that happens, nuclei form rod-like and slab-like structures and bubbles, termed nuclear pasta. The existence of pasta phases change the dynamics of neutron stars and how they behave astrophysically. New detailed simulations have shown how hot nucleic matter can form the various pasta phases as it cools. The matter seems to pass through a series of phases starting from uniform matter and heading through spherical, cylinder-like, slab-like phases and then as more uniform matter with holes that are cylindrical and then spherical before the whole lot becomes uniform again at a lower temperature.

Preprint: http://www.arxiv.org/abs/nucl-th/0205037

4) Electron liquid crystals
L. Radzihovsky and A. T. Dorsey
Physical Review Letters (Print issue: May 27, 2002)

Electrons don't normally know one direction from another, so researchers were perplexed a few years ago when they found a cold plane of electrons suddenly choosing to conduct many times better in one direction than in the perpendicular one. Maybe they could acquire a preferred orientation by acting like liquid crystals, theorists proposed. Now a group reports it has worked this theory out well enough that experimenters may finally have some detailed signs to search for.

Physical Review Focus: http://focus.aps.org/v9/st25.html
Journal article: http://link.aps.org/abstract/PRL/v88/e216802

5) Chromium atoms on demand
S. B. Hill, J. J. McClelland
APS Division of Atomic, Molecular, and Optical Physics meeting (May 28-June 1, 2002)

A NIST group can now supply chromium atoms on demand, one at a time, the first
'"/>

Contact: David Harris
harris@aps.org
301-209-3238
American Physical Society
15-May-2002


Page: 1 2 3 4

Related biology news :

1. Physics gravity model applicable to disease spread
2. Physics tip sheet #42
3. Physics tip sheet #41 - April 5, 2004
4. Physics tip sheet #39 - Nov. 17, 2003
5. Physics tip sheet #37
6. Physics tip sheet #36 - July 30, 2003
7. Physics tip sheet #34 - April 1, 2003
8. Physics tip sheet #33 March 28, 2003
9. Physics tip sheet #30 - January 9, 2003
10. Physics tip sheet #29 October 23, 2002
11. Physics tip sheet #21 July 10, 2002

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Physics tip sheet May

(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
(Date:5/30/2015)... May 30, 2015 CTI BioPharma Corp. (CTI ... business (NYSE: BAX ) today announced data from ... pacritinib for the treatment of myelofibrosis – in a ... of the American Society of Clinical Oncology (ASCO), May ... Pacritinib is an investigational oral multikinase inhibitor with ...
(Date:5/30/2015)... CHICAGO and RARITAN, N.J. ... the international, multi-center, open-label, two-part, single-arm Phase 2 ... – an investigational, human anti-CD38 monoclonal antibody – ... percent (95% CI, 20.8-38.9), as assessed by an ... multiple myeloma. The ORR was consistent among the ...
(Date:5/30/2015)... Texas , May 30, 2015  Caris ... from a study in which researchers identified biomarker ... metachronous paired glioma tumors, indicating changes in response ... observing 19 patients was a subset of a ... molecular heterogeneity of the cancer. These data utilizing ...
(Date:5/29/2015)... CHAPEL HILL, N.C. , May 29, 2015 ... the medical affairs function into roles involving clinical ... As its responsibilities have grown, Medical Affairs ... the function as a global group. And while ... sometimes find it challenging to identify strong performance ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2
Cached News: